Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium ( MHSRS )
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction ( ASR ) and frequency of acute stress disorder ( ASD ) and posttraumatic stress disorder ( PTSD ) expected to begin third quarter ...
| Ticker |
Sentiment |
Impact |
|
GOOG
|
Neutral
|
2 %
|
|
TNXP
|
Neutral
|
6 %
|
|
NRC
|
Neutral
|
2 %
|
